Medicare Value-Pricing Options Vary Widely In Part B Payment Experiment
Executive Summary
One option from CMS would adjust coinsurance to steer beneficiaries toward 'higher-value' drugs while other possible arrangements relate more directly to reducing Medicare payments.
You may also be interested in...
Medicare's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues
President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.
Part B's Foreign Price Bench-marking Will Only Hurt Bad Negotiators, HHS's Azar Argues
President Trump touts CMS proposal that would peg Part B prices to an international index in the hopes of lowering US costs; industry calls it foreign price controls and warns it will hinder access.
ICER Value Assessments Could Provide US Standard, Payers, Providers Tell HHS
Comments to HHS on the Trump Administration’s US drug pricing blueprint recommend that cost effectiveness analyses by the Institute for Clinical and Economic Review could help promote value-based pricing.